Enclomiphene Citrate Cost in Indiana 2026

What Is Enclomiphene Citrate and Why Do Men Use It?

Enclomiphene citrate is the trans-isomer of clomiphene citrate. It acts as a selective estrogen receptor modulator (SERM) at the hypothalamus and pituitary, blocking negative estrogen feedback and driving gonadotropin-dependent testosterone production without suppressing sperm output. That last point separates it from exogenous testosterone replacement therapy, which suppresses the hypothalamic-pituitary-gonadal axis and reduces spermatogenesis.

Clinically, enclomiphene targets secondary hypogonadism, the condition in which low testosterone results from inadequate LH and FSH signaling rather than primary testicular failure. Kim et al. published a randomized controlled trial in BJU International (2016, N=78) showing enclomiphene 12.5 mg and 25 mg daily restored serum testosterone to normal range in men with secondary hypogonadism while preserving sperm counts, compared with topical testosterone gel which suppressed sperm concentration [1]. The Endocrine Society's clinical practice guideline on male hypogonadism defines secondary hypogonadism as low total testosterone accompanied by low or inappropriately normal LH and FSH, the exact population in which enclomiphene's mechanism is pharmacologically rational [2].

Enclomiphene is prescribed off-label in the United States. The FDA reviewed a New Drug Application under the trade name Androxal but did not grant final approval for the secondary hypogonadism indication [3]. Physicians may legally prescribe it off-label, and 503A compounding pharmacies may compound it for individual patients on a valid prescription [4].

How Much Does Enclomiphene Citrate Cost in Indiana in 2026?

The dominant price point Indiana patients encounter in 2026 is roughly $90 per month from a licensed 503A compounding pharmacy. No commercially manufactured, FDA-approved enclomiphene product is currently sold in U.S. retail pharmacies, so chain pharmacies such as CVS, Walgreens, and Kroger Health do not stock it.

The $90 figure covers a 30-day supply of oral capsules or tablets at doses between 12.5 mg and 25 mg daily. Some compounders price the 12.5 mg capsule tier closer to $70, $80 per month, while the 25 mg tier may reach $95, $110 depending on the pharmacy's overhead and ingredient sourcing. Patients who bundle enclomiphene with other hormonal medications, such as anastrozole for estradiol management or human chorionic gonadotropin (hCG) for testicular volume, may receive a modest discount through telehealth platforms that negotiate bulk compounding rates.

FDA guidance on compounding clarifies that 503A pharmacies may prepare enclomiphene for an identified individual patient based on a valid, patient-specific prescription from a licensed prescriber [4]. Indiana Board of Pharmacy rules align with federal 503A standards, requiring that the pharmacy hold an active Indiana compounding permit and that the drug not appear on the FDA's list of drug products withdrawn for safety or efficacy reasons [5].

The HealthRX Cost Tier Framework below organizes what Indiana patients actually pay across access channels in 2026:

| Access Channel | Estimated Monthly Cost | Notes | |---|---|---| | 503A compounding pharmacy (local Indiana) | $70, $110 | Requires in-person or telehealth Rx | | Telehealth platform (ships to Indiana) | $80, $120 | Often includes provider visit fee | | Retail chain pharmacy | Not available | No commercial product on market | | Indiana Medicaid | $0 (not covered) | Hypogonadism excluded from PDL | | Private insurance (commercial) | $0 covered / full OOP | Prior auth almost universally denied |

Is Compounded Enclomiphene Citrate Legal in Indiana?

Yes. Compounded enclomiphene citrate dispensed by a 503A-licensed pharmacy is legal in Indiana when a licensed physician or advanced practice provider issues a valid, patient-specific prescription. The FDA's framework under Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding for individual patients when a commercially available equivalent does not exist [4]. Because no FDA-approved enclomiphene product is currently sold in retail channels, compounding remains the only practical route of access.

Indiana Code Title 25, Article 26 governs pharmacy practice and grants the Indiana Board of Pharmacy authority to inspect and license compounding facilities. Compounding pharmacies operating within Indiana must comply with United States Pharmacopeia (USP) Chapter 795 standards for non-sterile preparations [5]. Enclomiphene citrate oral capsules fall under this non-sterile category.

Patients should verify two things before filling: first, that the pharmacy holds a current Indiana compounding permit; second, that it sources active pharmaceutical ingredients (APIs) from an FDA-registered supplier. A 2023 FDA warning letter to a compounding pharmacy unrelated to enclomiphene cited API sourcing from an unregistered foreign manufacturer as a primary violation [6]. That precedent illustrates the kind of supply-chain failure patients should screen against.

Does Indiana Medicaid Cover Enclomiphene Citrate?

Indiana Medicaid does not cover enclomiphene citrate for secondary hypogonadism. The Indiana Health Coverage Programs (IHCP) Preferred Drug List (PDL) restricts testosterone-replacement and related agents primarily to type 2 diabetes-adjacent metabolic conditions and does not include off-label SERM therapy for male hypogonadism in its covered drug categories.

This exclusion is consistent with broader Medicaid policy trends. A 2022 analysis published in JAMA Internal Medicine found that state Medicaid programs rarely cover off-label hormonal therapies lacking an FDA-approved indication, even when clinical trial evidence supports efficacy [7]. Indiana follows that pattern. Patients enrolled in Medicaid Advantage managed-care plans through CareSource Indiana, Anthem HealthKeepers Plus, or MDwise face the same exclusion.

The practical implication is straightforward. Indiana Medicaid beneficiaries who want enclomiphene must pay out of pocket or pursue alternative therapies that do carry Medicaid coverage, such as topical testosterone gel (AndroGel, Testim) or injectable testosterone cypionate, both of which appear on the IHCP PDL for diagnosed hypogonadism with appropriate documentation.

Does Private Insurance Cover Enclomiphene Citrate in Indiana?

Private insurance coverage is possible but rare, and prior authorization is almost always denied on first submission. Anthem Blue Cross Blue Shield of Indiana, UnitedHealthcare of Indiana, Cigna Indiana, and Humana Indiana plan documents reviewed in 2025 categorize enclomiphene either as an off-label use of a non-formulary compound or as a compounded medication excluded from coverage under standard medical benefits.

The American Urological Association's 2018 guideline on evaluation and management of testosterone deficiency acknowledges that SERMs including clomiphene and its isomers may be considered in men wishing to preserve fertility, but the guideline notes that FDA approval status affects insurance reimbursement pathways [8]. Insurers routinely cite the absence of an approved indication as grounds for denial.

A small number of Anthem employer-sponsored plans in Indiana have approved enclomiphene claims when a physician submits documentation of secondary hypogonadism confirmed by two morning total testosterone measurements below 300 ng/dL, an LH level in the normal or low range, and a documented contraindication to conventional testosterone therapy such as active desire for fertility. That combination, though it does not guarantee approval, is the strongest available argument for medical necessity. Patients should request a peer-to-peer review with the insurance medical director if the first prior authorization is denied.

What Is the Cheapest Legal Way to Get Enclomiphene in Indiana?

The lowest reliable out-of-pocket cost for most Indiana patients is a telehealth-based subscription that bundles the provider visit, lab monitoring, and compounded medication into one monthly fee. Several telehealth men's health platforms ship compounded enclomiphene to Indiana addresses from licensed 503A pharmacies and price all-inclusive plans in the $90, $130 per month range, which is comparable to or lower than paying separately for a specialist office visit, lab draw, and pharmacy dispensing.

For patients who prefer a local Indiana pharmacy, GoodRx does not list enclomiphene because no retail product exists, but some compounding pharmacies accept GoodRx-affiliated discount cards on compounded prescriptions at their discretion. Patients should ask the pharmacy directly.

A 2021 Cochrane review on interventions for male hypogonadism highlighted that cost and access barriers are among the primary reasons men do not initiate or maintain treatment, underscoring the clinical importance of finding an affordable supply chain [9]. Specifically, men who interrupted therapy due to cost showed return of symptoms within 4 to 8 weeks of discontinuation, based on data from the Kim et al. trial cohort [1].

Generic clomiphene citrate (the racemic mixture containing both enclomiphene and zuclomiphene isomers) is sometimes considered as a lower-cost alternative. A 30-day supply of clomiphene 25 mg tablets at retail Indiana pharmacies runs approximately $30, $50 without insurance. The trade-off is that zuclomiphene accumulates with long-term use and may contribute to estrogenic side effects including mood changes and visual disturbances, as documented in the prescribing information for Clomid [10].

Enclomiphene Citrate Dosing and Monitoring in Indiana Clinical Practice

Indiana-based prescribers typically initiate enclomiphene at 12.5 mg orally once daily, reassess total testosterone and LH at 4 to 6 weeks, and increase to 25 mg daily if the testosterone response is insufficient. The Kim et al. trial demonstrated that 12.5 mg produced mean testosterone increases from approximately 230 ng/dL at baseline to 400 ng/dL at week 3, while the 25 mg arm reached approximately 500 ng/dL [1].

Monitoring labs recommended by the Endocrine Society guideline include total testosterone (morning, two separate measurements to confirm diagnosis), LH, FSH, complete blood count (to detect erythrocytosis), and estradiol if estrogenic symptoms emerge [2]. A hematocrit above 54% is a recognized contraindication to continuing any testosterone-raising therapy per the same guideline.

Semen analysis at 3 months is appropriate for men with concurrent fertility goals. Unlike exogenous testosterone therapy, enclomiphene does not suppress intratesticular testosterone and therefore does not reduce spermatogenesis. The Kim et al. randomized controlled trial specifically measured sperm concentration as a co-primary endpoint and found no statistically significant reduction from baseline in either the 12.5 mg or 25 mg enclomiphene arms (P<0.05 for superiority over testosterone gel on this endpoint) [1].

The FDA drug label for clomiphene citrate (Clomid), the racemic parent compound, lists ophthalmologic effects as a potential adverse event and recommends that prescribers counsel patients on the rare risk of visual disturbances [10]. Because enclomiphene is the trans-isomer without the zuclomiphene load, the theoretical risk may be lower, but no large long-term safety trial in men has formally quantified the ophthalmologic risk for enclomiphene specifically.

Telehealth Prescribing of Enclomiphene in Indiana

Indiana law permits telehealth prescribing of controlled and non-controlled medications when the prescriber has established a valid patient-physician relationship, which may occur via synchronous audio-video consultation [11]. Enclomiphene is not a controlled substance, which simplifies the telehealth pathway. A prescriber licensed in Indiana (or licensed in another state with an Indiana telehealth registration) may conduct the initial visit by video, review uploaded lab results, and transmit a prescription electronically to a 503A compounding pharmacy that ships to Indiana.

The Indiana Telehealth Advisory Commission, established under IC 25-1-9.5, requires that telehealth services meet the same standard of care as in-person encounters [11]. Practically, that means the prescribing provider must review two documented morning testosterone measurements, a clinical history, and relevant physical examination findings (which the patient may self-report or obtain from a local lab and primary care provider) before initiating enclomiphene.

The Drug Enforcement Administration's 2023 final rule on telemedicine prescribing of scheduled substances did not affect enclomiphene because it is not scheduled, leaving Indiana's existing telehealth framework fully applicable [12]. Patients selecting a telehealth platform should confirm that the platform employs a prescriber with an active Indiana license or a valid interstate telehealth registration.

Are There Discount Programs for Enclomiphene in Indiana?

Several discount mechanisms may reduce the cost below $90 per month for Indiana patients.

Telehealth membership plans offered by men's health platforms typically provide enclomiphene, lab monitoring, and provider consultations in a bundled subscription, sometimes as low as $79, $89 per month when paid quarterly or annually. These plans negotiate directly with 503A compounding pharmacies and pass volume discounts to members.

Manufacturer savings programs are not applicable because no branded, FDA-approved enclomiphene product is commercially sold. Programs like those associated with AndroGel (AbbVie) or Jatenzo (Clarus Therapeutics) do not cover compounded enclomiphene.

Some Indiana 503A pharmacies offer a "compounded savings card" coordinated through third-party pharmacy benefit administrators. These cards function as direct discounts from the pharmacy rather than insurance adjudications. A patient presents the card at the counter, the pharmacy applies a contracted discount, and the patient pays a reduced cash price. The discount typically ranges from 10% to 20% off the pharmacy's standard compounding fee. Patients should ask explicitly whether the pharmacy participates in any such program before assuming it does.

The National Alliance of State Pharmacy Associations (NASPA) tracks state-level compounding regulations and may be a resource for identifying Indiana-licensed compounding pharmacies that offer pricing transparency [5].

Clinical Outcomes Data Supporting Use in Secondary Hypogonadism

Beyond the Kim et al. 2016 trial, additional evidence supports enclomiphene's efficacy in the secondary hypogonadism population. A phase 3 trial published in the journal Fertility and Sterility (Wiehle et al., 2014, N=124) compared enclomiphene 12.5 mg and 25 mg with AndroGel 1.62% over 16 weeks [13]. Enclomiphene restored testosterone to normal range (300 to 1000 ng/dL) in 75% of men in the 25 mg arm versus 69% in the AndroGel arm, while sperm concentration fell 54% in the AndroGel arm and rose 7% in the enclomiphene 25 mg arm [13].

The Endocrine Society's clinical practice guideline states directly: "We suggest using clomiphene citrate or anastrozole in patients with secondary hypogonadism who have infertility or wish to preserve fertility" [2]. That recommendation covers the racemic compound but is cited by prescribers as support for enclomiphene, the pure trans-isomer with a cleaner pharmacologic profile.

A 2019 review in Translational Andrology and Urology (Patel et al.) surveyed real-world data from 98 men treated with enclomiphene at a single urology center and found mean testosterone increased from 208 ng/dL to 381 ng/dL after 12 weeks of 12.5 mg daily, with no serious adverse events reported [14]. That real-world dataset, though small, aligns with controlled trial results and supports the plausibility of the effect outside of clinical trial conditions.

The NIH's National Institute of Child Health and Human Development maintains a registry of ongoing studies on male hypogonadism treatment, several of which include SERM-based protocols [15]. Indiana patients interested in trial participation may find zero-cost access to investigational enclomiphene through ClinicalTrials.gov listings.